Core Viewpoint - The announcement details the completion and termination of the 2022 Employee Stock Ownership Plan (ESOP) of Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd, highlighting the acquisition of shares by the company's general manager and board member Wang Ke, reflecting confidence in the company's future development [1][5]. Group 1: Share Acquisition Details - Wang Ke acquired 22 million shares through block trading, representing 1.72% of the company's total share capital [3][4]. - Prior to the acquisition, Wang Ke held 63,409,600 shares, which was 4.95% of the total share capital [2][4]. - After the acquisition, Wang Ke's total shareholding increased to 85,409,600 shares, or 6.67% of the total share capital [4]. Group 2: Employee Stock Ownership Plan - The 2022 ESOP was approved in August 2022, with 30 million shares transferred to the plan's dedicated account at a price of 4.83 yuan per share, totaling 144.9 million yuan [5][6]. - The lock-up period for the ESOP ended on September 5, 2023, and the plan was extended for an additional 12 months in August 2024 [6]. - As of June 25, 2025, all shares held under the ESOP were sold, with 22 million shares sold to Wang Ke and the remaining 8 million shares sold through centralized bidding [6][7]. Group 3: Compliance and Governance - The share acquisition complies with relevant laws and regulations, ensuring that the company's shareholding structure remains within listing requirements [4][6]. - The acquisition is expected to enhance the company's governance structure and stabilize management control, reflecting the management's confidence in the company's long-term value [4][6].

Core Viewpoint - The announcement details the completion of a shareholding increase plan by Wang Ke, an action-in-concert party of the actual controller Wang Yaofang, reflecting confidence in the company's future development and long-term investment value [1][2]. Group 1: Shareholding Increase Details - Wang Ke has increased his shareholding by 9,600,000 shares from June 20, 2025, and an additional 12,400,000 shares from June 24 to 25, 2025, totaling 22,000,000 shares [1][3]. - After the increase, Wang Ke and Wang Yaofang collectively hold 340,811,600 shares, representing 26.63% of the total share capital [1][2]. Group 2: Shareholding Structure Before and After Increase - Before the increase, Wang Ke held 7,300,960 shares (6.67%), and after the increase, he holds 8,540,960 shares (6.67%) [2][3]. - Wang Yaofang's shareholding remains unchanged at 25,540,200 shares (19.96%) before and after the increase [2][3]. Group 3: Compliance and Regulations - The shareholding increase was conducted in accordance with relevant regulations, including the Securities Law and the Management Measures for the Acquisition of Listed Companies [3][4]. - Wang Ke has committed to not reducing his shareholding during the increase period and will complete the plan within the stipulated timeframe [3][4].

Core Viewpoint - The recent share acquisition by Wang Ke, a concerted actor of the actual controller of Qianhong Pharmaceutical, reflects confidence in the company's future development and long-term investment value [1][2]. Group 1: Shareholding Changes - Wang Ke has completed a share acquisition plan, increasing his holdings by 22 million shares, which corresponds to 1.72% of the company's total share capital [1][2]. - Following this acquisition, the combined shareholding of Wang Yao Fang and Wang Ke has risen to 26.63% [2]. - Zhao Gang, a significant shareholder and vice chairman, has reduced his holdings by 0.8117%, but this is not expected to negatively impact the company's operations [2]. Group 2: Company Performance - Qianhong Pharmaceutical is a leading player in the domestic biopharmaceutical sector, particularly in the heparin full industry chain, and has shown consistent high growth in performance [3][4]. - The company achieved a revenue of 1.526 billion yuan and a net profit of 356 million yuan in 2024, marking a year-on-year increase of 95.77% [4]. - In Q1 2025, the company maintained strong profit growth, with revenues of 451 million yuan and a net profit of 161 million yuan, reflecting a year-on-year increase of 54.62% [4]. Group 3: Innovation and R&D - The company is advancing multiple innovative drugs in various stages of clinical research, which is expected to enhance its core competitiveness and lay a foundation for future growth [5][6]. - As of the end of 2024, the company employed 188 R&D personnel, accounting for 19.20% of its total workforce, with R&D investment exceeding 150 million yuan, representing nearly 10% of total revenue [5][6]. - The company has made significant progress in biopharmaceutical innovation, with three innovative drugs entering Phase II clinical trials and several other projects underway [6].

证券代码：002550 证券简称：千红制药 公告编号：2025-019 关于公司董事、总经理受让公司员工持股计划部分股份暨公 司 2022 年核心员工持股计划出售完毕并终止的公告 公司股东王轲先生保证向本公司提供的信息内容真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务 人提供的信息一致。 常州千红生化制药股份有限公司（以下简称"本公司"或"公司"）于近日 收到公司董事、总经理王轲先生通知，基于对公司未来发展前景的信心和长期投 资价值的认可，已于 2025 年 6 月通过大宗交易方式受让公司 2022 年核心员工持 股计划所持有的 2200 万股公司股票，且公司收到华泰证券（上海）资产管理有 限公司通知，截止 2025 年 6 月 25 日，公司 2022 年核心员工持股计划所持公司 股票已全部出售完毕，2022 年核心员工持股计划实施完毕并终止。公司根据《关 于上市公司实施员工持股计划试点的指导意见》、《深圳证券交易所上市公司自律 监管指引第 1 号—主板上市公司规范运作》、《公司 2022 年核心员工持股计划（草 案）》及《深圳证券交易所上市公司自 ...

证券代码：002550 证券简称：千红制药 公告编号：2025-018 常州千红生化制药股份有限公司 关于实际控制人的一致行动人增持股份计划实施完成暨增持股 份触及 1%整数倍的公告 公司实际控制人王耀方先生的一致行动人王轲先生保证向本 公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提 供的信息一致。 常州千红生化制药股份有限公司（以下简称"公司"或"本公司"）于 20 25 年 6 月 25 日收到公司实际控制人王耀方先生的一致行动人王轲先生出具的 《增持股份计划实施完成暨增持股份触及 1%整数倍的告知函》，基于对公司未来 发展前景的信心和长期投资价值的认可，王轲先生已于 2025 年 6 月使用自有或 自筹资金通过大宗交易方式增持公司股份 9,600,000 股，本次于 6 月 24 日至 25 日继续增持公司股份 12,400,000 股，截至本公告披露日，累计增持公司股份 22, 000,000 股，占公司总股本比例 1.72%，本次增持计划已实施完成。 本次增持后，王轲先生及其一致行动人公司实际控制人王耀方先生合计持 有 ...

Core Viewpoint - A total of 14 listed companies announced share buybacks or increases in shareholdings this week, with significant involvement of loans for these activities [1][2]. Group 1: Companies Announcing Buybacks or Increases - Kailong High-Tech plans to repurchase shares worth between 25 million to 50 million yuan, with a loan of 25 million yuan [2]. - Hunan Haili intends to repurchase between 8.38 million to 16.76 million shares, supported by a loan of 200 million yuan [2]. - Guangda Special Materials aims to repurchase shares worth between 200 million to 400 million yuan, with a loan not exceeding 360 million yuan [2]. - Dahao Technology's controlling shareholder plans to increase shareholdings by 50 million to 100 million yuan [2]. - Qianhong Pharmaceutical's actual controller intends to continue increasing holdings by no less than 12.4 million shares [2]. - Bluetian Gas's controlling shareholder plans to increase holdings by 100 million to 150 million yuan, with a loan not exceeding 135 million yuan [2]. - Aikedi plans to repurchase shares worth between 100 million to 200 million yuan [2]. - Sichuan Changhong intends to repurchase shares worth between 250 million to 500 million yuan, with a loan not exceeding 450 million yuan [2]. - Qizhong Technology plans to repurchase shares worth between 75 million to 150 million yuan [2]. - Oriental Bio's chairman proposed a repurchase of shares not exceeding 50 million yuan [2]. - Yunlu Co. plans for directors and senior management to collectively increase holdings by 4 million to 12 million yuan [2]. - Hongli Zhihui's controlling shareholder plans to increase holdings by 25 million to 50 million yuan, with a loan not exceeding 45 million yuan [2]. - Dongfang Shenghong's controlling shareholder intends to increase holdings by 500 million to 1 billion yuan, with a loan not exceeding 900 million yuan [2]. - Midea Group plans to repurchase shares worth between 5 billion to 10 billion yuan, with a loan not exceeding 9 billion yuan [2].

Core Viewpoint - The report details the equity change of Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd., highlighting the increase in shareholding by the information disclosure obligor, Wang Ke, through block trading, reflecting confidence in the company's long-term investment value and future development prospects [1][6]. Group 1: Equity Change Details - Wang Ke increased his shareholding in Qianhong Pharmaceutical by acquiring 9.6 million shares at a price of 8.76 RMB per share, totaling 84.096 million RMB [6][8]. - Following the equity change, Wang Ke's direct shareholding rose to 73,009,600 shares, representing 5.70% of the total share capital, while the combined voting rights of Wang Ke and his concerted actor, Wang Yaofang, increased to 25.66% [7][8]. Group 2: Information Disclosure Obligors - Wang Ke and his concerted actor, Wang Yaofang, are both natural persons, with Wang Ke serving as the General Manager of Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. since September 2014 [2][3]. - Wang Yaofang, also a concerted actor, has been involved in the same company since April 2003, indicating a strong familial and operational connection between the two [4][5]. Group 3: Future Plans - Wang Ke plans to continue increasing his shareholding in the company within the next 12 months, estimating an additional purchase of approximately 12.4 million shares, depending on market conditions [6][7]. - There are currently no plans for significant changes to the company's main business operations, asset sales, mergers, or adjustments to the board of directors within the next year [10][11]. Group 4: Company Independence and Competition - The equity change will not affect the company's independence, as it will maintain its independent legal status and operational capabilities [12]. - There will be no new competition arising from this equity change, as the controlling shareholder and actual controller remain unchanged [12]. Group 5: Financial Transactions - The funds for the equity increase were sourced from Wang Ke's own and self-raised funds, with no involvement of related party transactions or asset swaps with the company [8][9]. - There have been no significant transactions between the information disclosure obligors and the company exceeding 30 million RMB in the past 24 months [12][13].

证券代码：002550 证券简称：千红制药 公告编号：2025-017 常州千红生化制药股份有限公司 关于实际控制人的一致行动人权益变动提示性公告 暨增持计划的公告 公司实际控制人王耀方先生的一致行动人王轲先生保证向本 公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提 供的信息一致。 常州千红生化制药股份有限公司（以下简称"公司"或"本公司"）于近 日收到公司实际控制人王耀方先生的一致行动人王轲先生出具的《详式权益变动 报告书》，基于对公司未来发展前景的信心和长期投资价值的认可，王轲先生已 于 2025 年 6 月通过大宗交易方式增持公司股份 9,600,000 股，占公司总股本比 例 0.75%。同时，王轲先生计划自本公告披露之日起 6 个月内通过大宗交易方式 继续增持公司股份。现将相关情况公告如下： 一、 权益变动情况 （一）本次权益变动基本情况 | 信息披露义务人 | 实际控制人王耀方先生的一致行动人王轲先生 | | --- | --- | | 住所 | 90 江苏省常州市新北区长江中路 号 | | 权益变动时间 | 202 ...

华泰联合证券有限责任公司 关于 常州千红生化制药股份有限公司 详式权益变动报告书 之 财务顾问核查意见 二〇二五年六月 声明 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司收购 管理办法》《公开发行证券公司信息披露内容与格式准则第15号——权益变动报 告书》《公开发行证券公司信息披露内容与格式准则第16号——上市公司收购报 告书》等相关法律、法规的规定，华泰联合证券有限责任公司按照行业公认的业 务标准、道德规范，本着诚实信用、勤勉尽责的精神，对本次权益变动的相关情况 和资料进行了核查，对《常州千红生化制药股份有限公司详式权益变动报告书》 所披露的内容出具核查意见。 本财务顾问特作出如下声明： 一、本财务顾问依据的有关资料由信息披露义务人提供。信息披露义务人已 向本财务顾问作出承诺，保证其所提供的资料均为真实、准确、完整的原始书面 资料或副本资料，副本资料或复印件与其原始资料或原件一致，所有文件的签名、 印章均是真实的；所有文件和材料不存在虚假记载、误导性陈述或重大遗漏，并 对所提供信息的真实性、准确性和完整性承担个别和连带的法律责任。 二、本财务顾问已按照规定履行尽职调查义务，有充分理由确信所 ...

智通财经6月19日电，千红制药(002550.SZ)公告称，公司实际控制人王耀方的一致行动人王轲于2025年 6月通过大宗交易方式增持公司股份960万股，占公司总股本比例0.75%。同时，王轲计划自本公告披露 之日起6个月内通过大宗交易方式继续增持公司股份，增持数量不少于1240万股。此次增持不会导致公 司控制权发生变更，也不会对公司持续经营产生重大影响。 千红制药：实际控制人一致行动人王轲拟继续增持不少于1240万股公司股份 ...